Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Mike Burgess"'
Autor:
Songbai Wang, Mike Burgess, Christopher Major, Alistair English, Maranna Sweeney, Arndt Hartmann
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 6, Iss 3, Pp 207-214 (2020)
Abstract Erdafitinib, a pan‐fibroblast growth factor receptor (FGFR) inhibitor received accelerated approval from the US Food and Drug Administration (FDA) for locally advanced or metastatic urothelial carcinoma (mUC) in adult patients with specifi
Externí odkaz:
https://doaj.org/article/5b71d872bc6740d1b167f4d9a6b1f1e9
Autor:
Adeela Kamal, Aurélie Candi, Matthias Versele, Bart Vanderhoydonck, Arnaud Marchand, Ron de Jong, Thuy Hoang, Georg Halder, Patrick Chaltin, Stephen L. Gwaltney, Mike Burgess
Publikováno v:
Cancer Research. 82:3945-3945
Background: The Hippo pathway is an evolutionarily conserved signaling cascade whose deregulation can promote excessive cell proliferation and tumor development. Pathway output is mediated by the YAP and TAZ transcriptional co-activators, which bind
Autor:
Maranna Sweeney, Christopher Major, Mike Burgess, Alistair English, Arndt Hartmann, Songbai Wang
Publikováno v:
The Journal of Pathology: Clinical Research
The Journal of Pathology: Clinical Research, Vol 6, Iss 3, Pp 207-214 (2020)
The Journal of Pathology: Clinical Research, Vol 6, Iss 3, Pp 207-214 (2020)
Erdafitinib, a pan‐fibroblast growth factor receptor (FGFR) inhibitor received accelerated approval from the US Food and Drug Administration (FDA) for locally advanced or metastatic urothelial carcinoma (mUC) in adult patients with specific FGFR3/2
Autor:
Mike Burgess, Lisa Eckstein, Heidi Beate Bentzen, Stephanie M. Fullerton, Eric M. Meslin, Barbara A. Koenig, Jane Kaye, Mahsa Shabani, Spero M. Manson, Kazuto Kato, Kieran C. O’Doherty, Edward S. Dove, Pascal Borry, Mildred K. Cho, Ryuichi Ida, Dianne Nicol, Kimberlyn McGrail, Adrian Thorogood, Jantina de Vries, Wylie Burke, Barbara Prainsack, Holly K. Tabor, Don Chalmers
In their Policy Forum "Toward unrestricted use of public genomic data" (25 January, p. 350), R. I. Amann et al. argue that once data has been cleared for release to the public domain by institutions, it should be open for use without further restrict
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6564881176deee6e10187eda1c7eafad
http://hdl.handle.net/10852/76217
http://hdl.handle.net/10852/76217
Publikováno v:
Water Resources Research. 37:2819-2823
Comprehensive, long-term hydrologic data sets for watershed systems are valuable for hydrologic process research; for interdisciplinary ecosystem analysis; for model development, calibration, and validation; and for assessment of change over time. Th
Autor:
Emma Mooney, Mike Burgess
Publikováno v:
British Journal of Neuroscience Nursing. 2:6-8
Mike Burgess and Emma Mooney discuss why younger people with stroke would benefit from an age-appropriate rehabiltation environment during their recovery.
Autor:
Franck Morschhauser, Gilles Salles, Thierry Lamy, Guillaume Cartron, Mike Burgess, Noel-Jean Milpied, Joe Birkett, Hervé Tilly, Catherine Thieblemont
Publikováno v:
Publons
RO5072759 (GA101) is the first humanized and glycoengineered monoclonal anti-CD20 antibody to enter clinical trials. Glycoengineeering results in a significantly increased antibody-dependent cytotoxicity (ADCC) compared to rituximab as shown in in vi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e49e62386227fbe9068d951973dbef92
https://publons.com/publon/26048882/
https://publons.com/publon/26048882/